A recent study shows that recommended bone mineral testing is rarely performed in men with prostate cancer receiving androgen deprivation therapy. Although these patients are at increased risk of fragility fracture, the reported incidence, from prospective randomized trials, is low. As a result, bone density testing for these men requires careful consideration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NCCN Clinical Practice Guidelines in Oncology™. Prostate cancer [online], (2008).
Morgans, A. K., Smith, M. R., O'Malley, A. J. & Keating, N. L. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer http://dx.doi.org/10.1002/cncr.27830.
National Osteoporosis Foundation. NOF Clinician's guide to prevention and treatment of osteoporosis [online], (2010).
Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).
Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005–1007 (2002).
WHO Collaborating Centre for Metabolic Bone Diseases. WHO Fracture Risk Assessment Tool (FRAX®) [online], (2012).
Planas, J. et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int. 104, 1637–1640 (2009).
Smith, M. R. et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345, 948–955 (2001).
Michaelson, M. D. et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol. 25, 1038–1042 (2007).
Yu, E. Y. et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J. Clin. Oncol. 30, 1864–1870 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares he has been a consultant for Amgen.
Rights and permissions
About this article
Cite this article
Yu, E. Bone density testing—essential or extraneous?. Nat Rev Urol 10, 11–12 (2013). https://doi.org/10.1038/nrurol.2012.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.240
